Brief: Syndax Announces Completion Of Enrollment In Augment-101 Pivotal Trial
28/03/2024 11:11
March 28 (Reuters) - Syndax Pharmaceuticals Inc
SNDX.O :
* SYNDAX ANNOUNCES COMPLETION OF ENROLLMENT IN AUGMENT-101
PIVOTAL
TRIAL COHORT OF PATIENTS WITH RELAPSED/REFRACTORY MNPM1 ACUTE
MYELOID LEUKEMIA
* TOPLINE DATA EXPECTED IN 4Q24 COULD SUPPORT SNDA FILING IN
1H25
* NDA IS UNDER REVIEW BY FDA FOR REVUMENIB IN R/R KMT2AR
ACUTE
LEUKEMIA WITH PDUFA ACTION DATE OF SEPT 26
Source text for Eikon: ID:nPn2CxRHfa
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million